Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a quick shot stop a heart attack in its tracks?

NCT ID NCT03487445

Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a single injection of selatogrel can rapidly prevent platelets from clumping together in adults having a heart attack. Participants receive either an 8 mg or 16 mg dose in the thigh, and researchers measure how quickly platelet activity drops. The goal is to see if this drug could provide a fast, easy way to reduce clot formation during a heart attack.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an injectable drug called selatogrel that prevents platelets from clumping together
What this could lead to
If it works, selatogrel could offer a fast-acting, easy-to-give treatment for heart attacks, potentially reducing damage to the heart.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may not work fast enough or could cause bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

48 people

The number who actually took part.

Started

Jul 2018

Finished

Nov 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Informed consent obtained prior to any study-mandated procedure, * Males aged from 18 to 85 and postmenopausal females aged up to 85 years, * Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization, * Subjects presenting a type I AMI including STEMI or NSTEMI. Main Exclusion Criteria: * Cardiogenic shock or severe hemodynamic instability, * Cardiopulmonary resuscitation, * Loading dose of any oral P2Y12 receptor antagonist prior to randomization, * Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization, * Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease). * Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding. * Known clinically important anemia. * Oral anticoagulation therapy within 7 days prior to randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction

Contacts and locations

Locations

  • Cardiocentro Ticino

    Lugano, 6900, Switzerland

  • Galilee Medical Center

    Nahariya, 22100, Israel

  • OLV Ziekenhuis Aalst

    Aalst, 9300, Belgium

  • UZLeuven

    Leuven, 3000, Belgium

  • University Hospital Bern

    Bern, 3010, Switzerland

  • Universitätsspital Basel

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.